23:21 , Jan 9, 2018 |  BC Extra  |  Company News

Management tracks: OncoMed, Neurocrine

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman, President and CEO Paul Hastings has resigned. The company is seeking a replacement. Perry Karsen will serve as chairman. Hastings began a medical leave of absence on...
23:25 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

Amplyx reports Phase I data for APX001 in fungal infections

In October, Amplyx Pharmaceuticals Inc. (San Diego, Calif.) reported data from two Phase I trials in 166 healthy volunteers showing that oral and IV APX001 were well tolerated at all doses tested. Additionally, the company...
23:54 , Aug 4, 2017 |  BioCentury  |  Finance

Fungal flexibility

Undisclosed first-in-human safety data persuaded a host of new investors to infuse Amplyx Pharmaceuticals Inc. with enough cash to pursue multiple indications for its broad-spectrum antifungal, APX001. On Aug. 2, the biotech raised $67 million...
16:47 , Aug 4, 2017 |  BC Week In Review  |  Financial News

Amplyx raises $67M in series C

Anti-infectives company Amplyx Pharmaceuticals Inc. (San Diego, Calif.) raised $67 million in an oversubscribed series C round led by Sofinnova Ventures on Aug. 2. Also participating were new investors Lundbeckfonden Ventures, Arix Bioscience and Pappas...
20:40 , Aug 2, 2017 |  BC Extra  |  Financial News

Amplyx raises $67M in series C

Anti-infectives company Amplyx Pharmaceuticals Inc. (San Diego, Calif.) raised $67 million in an oversubscribed series C round led by Sofinnova Ventures. Also participating were new investors Lundbeckfonden Ventures, Arix Bioscience and Pappas Capital, and existing...
01:19 , Jan 14, 2017 |  BC Extra  |  Company News

Management tracks

Rare diseases company Swedish Orphan Biovitrum AB (SSE:SOBI) said CEO Geoffrey McDonough will leave the company on July 1. The company is searching for a replacement. The company also named Armin Reininger SVP and head...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

IV APX001: Phase I started

Amplyx began a double-blind, placebo-controlled, dose-escalation, European Phase I trial to evaluate single and multiple doses of IV APX001 in about 80 healthy volunteers. The company plans to begin Phase I testing of oral APX001...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Clinical News

APX001 regulatory update

Amplyx Pharmaceuticals Inc. , San Diego, Calif.   Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan   Product: APX001   Business: Infectious   FDA granted Qualified Infectious Disease Product (QIDP) designation to APX001 from Amplyx to treat...
08:00 , Feb 15, 2016 |  BC Week In Review  |  Financial News

Amplyx financial update

Amplyx Pharmaceuticals Inc. , San Diego, Calif.   Business: Infectious   Date announced: 2016-02-09   Note: Amplyx raised $8 million in an extension of a series B round, bringing the total raised in the round...
01:27 , Feb 10, 2016 |  BC Extra  |  Company News

Management tracks

Immunology company Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) hired James Bucher as SVP and general counsel. Bucher was VP of corporate legal affairs and corporate compliance officer at Exelixis Inc. (NASDAQ:EXEL). Medgenics Inc. (NYSE-M:MDGN) promoted VP of...